Evaluation of Overall Survival in Patients With Anaplastic Thyroid Carcinoma, 2000-2019

This cohort study (n=479) found survival increased over time (e.g. 2-year OS 18% in 2000-2013 v 42% in 2017-2019). Factors associated with improved OS included targeted therapy (HR 0.49; 95% CI 0.39-0.63; P <0.001), and the addition of immunotherapy (0.58; 0.36-0.94; P=0.03).

JAMA Oncology